Eli Lilly hits the gas on tirzepatide in obesity, nabs rolling submission for potential blockbuster indication
In the already buzzy obesity drug market, Eli Lilly is the latest newsmaker, nabbing a fast-track designation and rolling review from the FDA on Thursday.
While Lilly’s tirzepatide study in obesity initially read out positive results in April, it’s initiating an FDA filing as it awaits results from a second Phase III study.
Lilly’s initial SURMOUNT-1 study showed up to 22% weight loss, and as it noted to Endpoints News recently, those results are beginning to approach levels of bariatric surgery which averages 25-30% of body weight loss.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.